CompletedPhase 2

Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Japan5 participantsStarted 2014-07

Plain-language summary

This study investigates the efficacy and safety of Lenalidomide as a treatment for recurrent or refractory POEMS (Crow-Fukase) syndrome.

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Patients who have been administered, bortezomib, lenalidomide, melpharan within 4 weeks prior to the registration.
✕. Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2 weeks prior to the registration.
✕. Patients who have been administered bevacizumab within 12 weeks prior to the registration.
✕. Patients who could worsen acutely during the clinical trial period.
✕. Patients with severe complicaitons ( cardiac failure, renal failure liver failure, bleeding enterogastric ulcer, ileus, poorly controlled diabetes.
✕. Patients with malignancies.
✕. Female patients who are pregnant or desire childbearing. Males who desire fertility.
✕. Patients who allergic to lenalidomide or dexamethasone.

Reduction rate of serum VEGF

Timeframe: after 24 weeks

NCT IDNCT02193698

SponsorChiba University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-10

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Patients who have been administered, bortezomib, lenalidomide, melpharan within 4 weeks prior to the registration.
✕. Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2 weeks prior to the registration.
✕. Patients who have been administered bevacizumab within 12 weeks prior to the registration.
✕. Patients who could worsen acutely during the clinical trial period.
✕. Patients with severe complicaitons ( cardiac failure, renal failure liver failure, bleeding enterogastric ulcer, ileus, poorly controlled diabetes.
✕. Patients with malignancies.
✕. Female patients who are pregnant or desire childbearing. Males who desire fertility.
✕. Patients who allergic to lenalidomide or dexamethasone.